

INTERNATIONAL
EDITION

Mc
Graw
Hill
Education

APPLIED CLINICAL PHARMACOKINETICS

3RD EDITION



LARRY A. BAUER



Applied Clinical Pharmacokinetics

Third Edition

Larry A. Bauer, PharmD

*Professor
Department of Pharmacy
School of Pharmacy*

*Adjunct Professor
Department of Laboratory Medicine
School of Medicine
University of Washington
Seattle, Washington*

Accession no. **M 0151271**

Date received **25 OCT 2016**

Call no. 615.7
3344 A
2014

**Mc
Graw
Hill**
Education

Medical

New York Chicago San Francisco Athens London Madrid Mexico City
Milan New Delhi Singapore Sydney Toronto

Applied Clinical Pharmacokinetics, 3rd edition

Copyright © 2014 by McGraw-Hill Education. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous editions copyright © 2008, 2001 by The McGraw-Hill Companies, Inc.

1 2 3 4 5 6 7 8 9 0 DOC/DOC 18 17 16 15 14

ISBN 978-0-07-179458-9

MHID 0-07-179458-1

This book was set in Times by Cenveo® Publisher Services.
The editors were Michael Weitz and Christina M. Thomas.
The production supervisor was Catherine Saggese.
Project management was provided by Vastavikta Sharma, Cenveo Publisher Services.
RR Donnelley was printer and binder.

This book is printed on acid-free paper.

Library of Congress Cataloging-in-Publication Data

Bauer, Larry A., author

Applied clinical pharmacokinetics / by Larry A. Bauer.—Third edition.

p. : cm.

Includes bibliographical references and index.

ISBN 978-0-07-179458-9 (hardcover : alk. paper)—ISBN 0-07-179458-1

(hardcover : alk. paper)

I. Title.

[DNLM: 1. Pharmacokinetics. 2. Pharmaceutical Preparations—administration & dosage. QV 38]

RM301.5

615'.7—dc23

2013029778

International Edition ISBN 978-1-25-925141-2; MHID 1-25-925141-1. Copyright © 2014. Exclusive rights by McGraw-Hill Education, for manufacture and export. This book cannot be re-exported from the country to which it is consigned by McGraw-Hill Education. The International Edition is not available in North America.

McGraw-Hill Education books are available at special quantity discounts to use premiums and sales promotions, or for use in corporate training programs. To contact a representative please visit the Contact Us pages at www.mhprofessional.com.

Dedication

Third time's a charm . . . right? Through the planned and unexpected, the little things and the big things, the pleasant side trips and trying travails, family are what make it all worthwhile. Thank you (S.P.B., L.A.B., and L.E.B.) for all of your love and support that helped make the third edition a reality.

Thanks for the huge amount of support and assistance from my colleagues. You guys help each and every day, whether it is insight on a new drug interaction, discussion of an interesting patient case, or the latest sports scores: John R. Horn, Douglas J. Black, Lingtak-Neander Chan, Danny D. Shen, and, of course, Philip D. Hansten.

"It's pretty far, but it doesn't seem like it."—Yogi Berra

—L.A.B.

Contents

About the Author ix

Foreword x

*From Applied Clinical Pharmacokinetics,
Second Edition xi*

*From Applied Clinical Pharmacokinetics,
First Edition xii*

I. Basic concepts

1. Clinical Pharmacokinetic and Pharmacodynamic Concepts 3

- Introduction 3
- Linear Versus Nonlinear Pharmacokinetics 3
- Clearance 6
- Volume of distribution 14
- Half-life and Elimination Rate Constant 16
- Michaelis-Menten or Saturable Pharmacokinetics 19
- Bioavailability 20
- Problems 22
- Answers to Problems 23

2. Clinical Pharmacokinetic Equations and Calculations 27

- Introduction 27
- One-Compartment Model Equations for Linear Pharmacokinetics 27
- Designing Individualized Dosage Regimens Using One-Compartment Model Equations 38
- Multicompartment Models 41
- Michaelis-Menten Equations for Saturable Pharmacokinetics 41
- Calculation of Clearance, Volume of Distribution, and Half-life in Pharmacokinetic Research Studies 42
- Problems 43
- Answers to Problems 44

3. Drug Dosing in Special Populations: Renal and Hepatic Disease, Dialysis, Heart Failure, Obesity, and Drug Interactions 49

- Introduction 49
- Renal Disease 49

- Hepatic Disease 56
- Heart Failure 64
- Dialysis 65
- Hemodialysis 67
- Hemofiltration 71
- Peritoneal Dialysis 73
- Obesity 74
- Drug Interactions 76
- Problems 79
- Answers to Problems 81

II. Antibiotics

4. The Aminoglycoside Antibiotics 89

- Introduction 89
- Therapeutic and Toxic Concentrations 89
- Clinical Monitoring Parameters 92
- Basic Clinical Pharmacokinetic Parameters 93
- Effects of Disease States and Conditions on Aminoglycoside Pharmacokinetics and Dosing 95
- Drug Interactions 100
- Initial Dosage Determination Methods 100
- Use of Aminoglycoside Serum Concentrations to Alter Dosages 121
- Bayesian Pharmacokinetic Computer Programs 146
- Dosing Strategies 149
- Special Dosing Considerations 150
- Problems 152
- Answers to Problems 156

5. Vancomycin 197

- Introduction 197
- Therapeutic and Toxic Concentrations 197
- Clinical Monitoring Parameters 200
- Basic Clinical Pharmacokinetic Parameters 201

- Effects of Disease States and Conditions on Vancomycin Pharmacokinetics and Dosing 202
- Drug Interactions 205
- Initial Dosage Determination Methods 205
- Use of Vancomycin Serum Concentrations to Alter Dosages 224
- Area Under the Curve Method 241
- Bayesian Pharmacokinetic Computer Programs 241
- Dosing Strategies 246
- Problems 247
- Answers to Problems 250

III. Cardiovascular Agents

6. Digoxin 293

- Therapeutic and Toxic Concentrations 293
- Clinical Monitoring Parameters 295
- Basic Clinical Pharmacokinetic Parameters 296
- Effects of Disease States and Conditions on Digoxin Pharmacokinetics and Dosing 296
- Drug Interactions 299
- Initial Dosage Determination Methods 300
- Pharmacokinetic Dosing Method 301
- Use of Digoxin Serum Concentrations to Alter Dosages 309
- Bayesian Pharmacokinetic Computer Programs 313
- Dosing Strategies 315
- Special Dosing Considerations 316
- Problems 320
- Answers to Problems 322

7. Lidocaine 339

- Introduction 339
- Therapeutic and Toxic Concentrations 339
- Clinical Monitoring Parameters 342
- Basic Clinical Pharmacokinetic Parameters 342
- Effects of Disease States and Conditions on Lidocaine Pharmacokinetics and Dosing 343
- Drug Interactions 347
- Initial Dosage Determination Methods 347
- Use of Lidocaine Serum Concentrations to Alter Doses 353
- Bayesian Pharmacokinetic Computer Programs 357
- Dosing Strategies 359
- Use of Lidocaine Booster Doses to Immediately Increase Serum Concentrations 359
- Problems 360
- Answers to Problems 361

8. Procainamide/*N*-acetyl Procainamide 373

- Introduction 373
- Therapeutic and Toxic Concentrations 373
- Clinical Monitoring Parameters 375
- Basic Clinical Pharmacokinetic Parameters 376
- Effects of Disease States and Conditions on Procainamide Pharmacokinetics and Dosing 377
- Drug Interactions 380
- Initial Dosage Determination Methods 380
- Use of Procainamide and *N*-Acetylprocainamide Serum Concentrations to Alter Doses 387
- Chien Method 393
- Bayesian Pharmacokinetic Computer Programs 394
- Use of Procainamide Booster Doses to Immediately Increase Serum Concentrations 396
- Dosing Strategies 397
- Conversion of Procainamide Doses From Intravenous to Oral Route of Administration 397
- Problems 398
- Answers to Problems 400

9. Quinidine 415

- Introduction 415
- Therapeutic and Toxic Concentrations 415
- Clinical Monitoring Parameters 416
- Basic Clinical Pharmacokinetic Parameters 417
- Effects of Disease States and Conditions on Quinidine Pharmacokinetics and Dosing 418
- Drug Interactions 420
- Initial Dosage Determination Methods 421
- Use of Quinidine Serum Concentrations to Alter Doses 426
- Dosing Strategies 432
- Conversion of Quinidine Doses From One Salt Form to Another 433
- Problems 434
- Answers to Problems 435

IV. Anticonvulsants

10. Phenytoin/Fosphenytoin 447

- Introduction 447
- Therapeutic and Toxic Concentrations 449
- Clinical Usefulness of Unbound Phenytoin Concentrations 450
- Clinical Monitoring Parameters 453

- Basic Clinical Pharmacokinetic Parameters 453
 Impact of Altered Plasma Protein Binding on Phenytoin Pharmacokinetics 457
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 458
 Drug Interactions 460
 Initial Dosage Determination Methods 462
 Literature-Based Recommended Dosing 466
 Use of Phenytoin Serum Concentrations to Alter Doses 468
 Bayesian Pharmacokinetic Computer Programs 481
 Dosing Strategies 483
 Use of Phenytoin Booster Doses to Immediately Increase Serum Concentrations 483
 Problems 485
 Answers to Problems 486
- 11. Carbamazepine 503**
 Introduction 503
 Therapeutic and Toxic Concentrations 503
 Clinical Monitoring Parameters 506
 Basic Clinical Pharmacokinetic Parameters 506
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 508
 Drug Interactions 509
 Initial Dosage Determination Methods 510
 Use of Carbamazepine Serum Concentrations to Alter Doses 511
 Bayesian Pharmacokinetic Computer Programs 512
 Problems 512
 Answers to Problems 513
- 12. Valproic Acid 517**
 Introduction 517
 Therapeutic and Toxic Concentrations 517
 Clinical Monitoring Parameters 521
 Basic Clinical Pharmacokinetic Parameters 521
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 523
 Drug Interactions 524
 Initial Dosage Determination Methods 526
 Use of Valproic Acid Serum Concentrations to Alter Doses 530
 Pharmacokinetic Parameter Method 532
 Bayesian Pharmacokinetic Computer Programs 534
 Dosing Strategies 536
 Problems 537
 Answers to Problems 538
- 13. Phenobarbital/Primidone 549**
 Introduction 549
 Therapeutic and Toxic Concentrations 549
 Clinical Monitoring Parameters 551
 Basic Clinical Pharmacokinetic Parameters 552
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 552
 Drug Interactions 554
 Initial Dosage Determination Methods 554
 Use of Phenobarbital and Primidone Serum Concentrations to Alter Doses 559
 Bayesian Pharmacokinetic Computer Programs 562
 Dosing Strategies 563
 Problems 564
 Answers to Problems 565
- 14. Ethosuximide 573**
 Introduction 573
 Therapeutic and Toxic Concentrations 575
 Clinical Monitoring Parameters 575
 Basic Clinical Pharmacokinetic Parameters 576
 Effects of Disease States and Conditions on Pharmacokinetics and Dosing 576
 Drug Interactions 577
 Initial Dosage Determination Methods 577
 Use of Ethosuximide Serum Concentrations to Alter Doses 580
 Bayesian Pharmacokinetic Computer Programs 583
 Dosing Strategies 585
 Problems 585
 Answers to Problems 586
- 15. Lamotrigine 593**
 Introduction 593
 Therapeutic and Toxic Concentrations 595
 Clinical Monitoring Parameters 595
 Basic Clinical Pharmacokinetic Parameters 596
 Effects of Diseases and Conditions on Pharmacokinetics and Dosing 597
 Drug Interactions 600
 Initial Dosage Determination Methods 603
 Use of Lamotrigine Serum Concentrations to Alter Doses 607
 Selection of Appropriate Pharmacokinetic Model and Equations 608
 Bayesian Pharmacokinetics Computer Programs 609
 Special Dosing Considerations 610
 Problems 610
 Answers to Problems 611

16. Levetiracetam 619

- Introduction 619
- Therapeutic and Toxic Concentrations 621
- Clinical Monitoring Parameters 621
- Basic Clinical Pharmacokinetic Parameters 622
- Effects of Disease States and Conditions on Pharmacokinetics and Dosing 625
- Drug Interactions 627
- Initial Dosage Determination Methods 628
- Use of Levetiracetam Serum Concentrations to Alter Doses 633
- Bayesian Pharmacokinetic Computer Programs 638
- Dosing Strategies 639
- Special Dosing Considerations 640
- Problems 640
- Answers to Problems 641

17. Oxcarbazepine/Eslicarbazepine 653

- Introduction 653
- Oxcarbazepine* 656
- Therapeutic and Toxic Concentrations 656
- Clinical Monitoring Parameters 656
- Basic Clinical Pharmacokinetic Parameters 656
- Effects of Disease States and Conditions on Pharmacokinetics and Dosing 658
- Drug Interactions 660
- Initial Dosage Determination Methods 661
- Use of MHD Serum Concentrations to Alter Doses of Oxcarbazepine 664
- Bayesian Pharmacokinetics Computer Programs 665
- Eslicarbazepine* 666
- Introduction 666
- Therapeutic and Toxic Concentrations 666
- Clinical Monitoring Parameters 667
- Basic Clinical Pharmacokinetic Parameters 667
- Effects of Disease States and Conditions on Pharmacokinetics and Dosing 668
- Drug Interactions 670
- Initial Dosage Determination Methods 671
- Use of Serum Concentrations to Alter Doses of Eslicarbazepine 672
- Bayesian Pharmacokinetics Computer Programs 674
- Problems 674
- Answers to Problems 675

V. Immunosuppressants**18. Cyclosporine 685**

- Introduction 685
- Therapeutic and Toxic Concentrations 685

- Clinical Monitoring Parameters 687
- Basic Clinical Pharmacokinetic Parameters 688
- Effects of Disease States and Conditions on Cyclosporine Pharmacokinetics and Dosing 690
- Drug Interactions 690
- Initial Dosage Determination Methods 691
- Use of Cyclosporine Concentrations to Alter Doses 694
- Bayesian Pharmacokinetic Computer Programs 699
- Dosing Strategies 701
- Problems 701
- Answers to Problems 703

19. Tacrolimus 713

- Introduction 713
- Therapeutic and Toxic Concentrations 713
- Clinical Monitoring Parameters 715
- Basic Clinical Pharmacokinetic Parameters 716
- Effects of Disease States and Conditions on Tacrolimus Pharmacokinetics and Dosing 717
- Drug Interactions 717
- Initial Dosage Determination Methods 718
- Use of Tacrolimus Concentrations to Alter Doses 720
- Bayesian Pharmacokinetic Computer Programs 724
- Dosing Strategies 726
- Problems 727
- Answers to Problems 728

20. Sirolimus 737

- Introduction 737
- Therapeutic and Toxic Concentrations 737
- Clinical Monitoring Parameters 739
- Basic Clinical Pharmacokinetic Parameters 740
- Effects of Disease States and Conditions on Sirolimus Pharmacokinetics and Dosing 741
- Drug Interactions 744
- Initial Dosage Determination Methods 745
- Use of Sirolimus Concentrations to Alter Doses 749
- Bayesian Pharmacokinetic Computer Programs 753
- Dosing Strategies 754
- Problems 754
- Answers to Problems 756

VI. Other Drugs**21. Lithium 767**

- Introduction 767
- Therapeutic and Toxic Concentrations 767
- Clinical Monitoring Parameters 768
- Basic Clinical Pharmacokinetic Parameters 769
- Effects of Disease States and Conditions on Lithium Pharmacokinetics 770
- Drug Interactions 770
- Initial Dosage Determination Methods 771
- Use of Lithium Serum Concentrations to Alter Dosages 780
- Dosing Strategies 783
- Problems 784
- Answers to Problems 785

22. Theophylline 797

- Introduction 797
- Therapeutic and Toxic Concentrations 799
- Clinical Monitoring Parameters 798

- Basic Clinical Pharmacokinetic Parameters 800
- Effects of Disease States and Conditions on Theophylline Pharmacokinetics and Dosing 800
- Drug Interactions 803
- Initial Dosage Determination Methods 804
- Use of Theophylline Serum Concentrations to Alter Doses 812
- Chiao Method 818
- Bayesian Pharmacokinetic Computer Programs 820
- Dosing Strategies 822
- Use of Theophylline Booster Doses to Immediately Increase Serum Concentrations 822
- Conversion of Theophylline Doses From Intravenous to Oral Route of Administration 823
- Removal of Theophylline Body Stores in Management of Theophylline Overdose 824
- Problems 825
- Answers to Problems 826

Index 847

About the Author

Larry A. Bauer, PharmD, is a Professor at the University of Washington School of Pharmacy and has been on the faculty since 1980. He also holds an adjunct appointment at the same rank in the Department of Laboratory Medicine where he is a toxicology consultant. He received a Bachelor of Science in Pharmacy degree (1977, Magna Cum Laude) from the University of Washington and a Doctor of Pharmacy degree (1980) from the University of Kentucky under the supervision of Dr. Robert Blouin. He also completed an ASHP-accredited hospital pharmacy residency (1980) specializing in clinical pharmacokinetics from A. B. Chandler Medical Center at the University of Kentucky under the preceptorship of Dr. Paul Parker. Dr. Bauer is a fellow of the American College of Clinical Pharmacology and the American College of Clinical Pharmacy.

Dr. Bauer's specialty area is in clinical pharmacokinetics, and he teaches courses and offers clinical clerkships in this area. His research interests include the pharmacokinetics and pharmacodynamics of drug interactions, the effects of liver disease and age on drug metabolism, and computer modeling of population pharmacokinetics. He has over 165 published research papers, abstracts, books and book chapters. Dr. Bauer is a member of several clinical pharmacology and clinical pharmacy professional organizations. He was Consulting Editor of *Clinical Pharmacy* (1981–1990), Field Editor of *ASHP Signal* (1981–1983), and a member of the Editorial Board of *Clinical Pharmacology and Therapeutics*. Recently, he completed an appointment to the Editorial Board of *Antimicrobial Agents and Chemotherapy* and, he reviews for many other scientific publications. Dr. Bauer has precepted three post-doctoral fellows in clinical pharmacokinetics who currently have faculty appointments in schools of pharmacy or positions in the pharmaceutical industry.